• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza A virus shedding reduction observed at 12 weeks post-vaccination when newborn pigs are administered live-attenuated influenza virus vaccine

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses. 2019 Mar 6. doi: 10.1111/irv.12630. [Epub ahead of print]
[h=1]Influenza A virus shedding reduction observed at 12 weeks post-vaccination when newborn pigs are administered live-attenuated influenza virus vaccine.[/h] Kaiser TJ[SUP]1[/SUP], Smiley RA[SUP]1[/SUP], Fergen B[SUP]2[/SUP], Eichmeyer M[SUP]2[/SUP], Genzow M[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza A virus in swine (IAV-S) causes an acute respiratory disease of swine which results in great economic losses. A bivalent H1N1 and H3N2, NS1-truncated live-attenuated IAV-S vaccine (LAIV, Ingelvac Provenza[SUP]?[/SUP] ) has recently become available.
[h=4]OBJECTIVE:[/h] Reduction of shedding during an outbreak in the nursery or finisher is an important parameter from an epidemiological control strategy; therefore, a laboratory efficacy study was conducted to evaluate nasal virus shedding when vaccinated pigs were challenged with either heterologous H1N2 or H3N2 strains 12 weeks post-vaccination.
[h=4]METHODS:[/h] Between 1 and 5 days of age, pigs born to IAV-S seronegative dams were intranasally administered 1 mL of vaccine or saline. At 30 days post-vaccination, pigs were weaned and randomized into two different challenge groups consisting of vaccinated pigs and control pigs commingled within pens for the two challenge groups. At 85 days post-vaccination, pigs in the first group were challenged with A/Swine/North Carolina/001169/2006 H1N2 challenge strain, and the second group was challenged with A/Swine/Nebraska/97901-10/2008 H3N2. Nasal swabs were collected daily for five days and tested by virus isolation.
[h=4]RESULTS AND CONCLUSION:[/h] This study showed significant reduction in nasal virus shedding with regard to both frequency and duration. A 1 mL intranasal dose of Ingelvac Provenza[SUP]?[/SUP] given as early as 1 day of age showed protection for at least 12 weeks later as evidenced by the reduction of shedding live, viable virus after challenge with either a heterologous H1N2 strain or a heterologous H3N2 strain.
? 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.


[h=4]KEYWORDS:[/h] LAIV; influenza A; influenza A virus in swine; pig; shedding; vaccination

PMID: 30843324 DOI: 10.1111/irv.12630
Free full text
 
Back
Top Bottom